Literature DB >> 11241053

Familial hemolytic uremic syndrome associated with complement factor H deficiency.

D Landau1, H Shalev, G Levy-Finer, A Polonsky, Y Segev, L Katchko.   

Abstract

Atypical hemolytic uremic syndrome (HUS) associated with factor H deficiency (FHD) carries a poor prognosis. A 3-year-old girl with FHD-HUS reached end-stage renal disease at age 6 months after experiencing numerous relapses; she underwent a cadaveric renal transplant at age 46 months. One month after transplantation, she experienced an extensive non-hemorrhagic cerebral infarction. Later, hematologic and renal manifestations of HUS developed, followed by another massive cerebral infarction and death in spite of multiple plasma transfusions. A 14-month-old boy with FHD-HUS experienced numerous HUS episodes starting at the age of 2 weeks. Daily plasma transfusions during relapses brought about only a temporary state of remission. However, prophylactic twice-weekly plasma therapy has been successful in preventing relapses and preserving renal function. With this regimen, serum factor H was increased from 6 mg/dL to subnormal values of 12 to 25 mg/dL (normal >60 mg/dL). We conclude that FHD-HUS recurs because FHD is not corrected by renal transplantation. A hypertransfusion protocol may prevent FHD-HUS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11241053     DOI: 10.1067/mpd.2001.112649

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  28 in total

1.  A favorable outcome of hemolytic uremic syndrome with factor H deficiency.

Authors:  Z Birsin Ozçakar; Fatoş Yalçinkaya; Emel Derelli; Banu Acar; Selçuk Yüksel; Ozden Tulunay; Mesiha Ekim
Journal:  Pediatr Nephrol       Date:  2004-05-11       Impact factor: 3.714

Review 2.  Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013.

Authors:  Caitlin E Carter; Nadine M Benador
Journal:  Pediatr Nephrol       Date:  2013-06-29       Impact factor: 3.714

3.  A case of atypical hemolytic uremic syndrome with a transient decrease in complement factor H.

Authors:  Hyewon Hahn; Eun Young Um; Young Seo Park; Hae Il Cheong
Journal:  Pediatr Nephrol       Date:  2005-12-17       Impact factor: 3.714

4.  Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.

Authors:  Gema Ariceta; Nesrin Besbas; Sally Johnson; Diana Karpman; Daniel Landau; Christoph Licht; Chantal Loirat; Carmine Pecoraro; C Mark Taylor; Nicole Van de Kar; Johan Vandewalle; Lothar B Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-09-18       Impact factor: 3.714

5.  Hemolytic uremic syndrome due to homozygous factor H deficiency.

Authors:  Sidharth Kumar Sethi; Dragon-Durey Marie-Agnes; Neelam Thaker; Pankaj Hari; Arvind Bagga
Journal:  Clin Exp Nephrol       Date:  2009-07-01       Impact factor: 2.801

6.  Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice.

Authors:  Fadi Fakhouri; Elena Goicoechea de Jorge; Frédérique Brune; Philippe Azam; H Terence Cook; Matthew C Pickering
Journal:  Kidney Int       Date:  2010-05-05       Impact factor: 10.612

7.  Eculizumab in neonatal hemolytic uremic syndrome with homozygous factor H deficiency.

Authors:  Katell Michaux; Justine Bacchetta; Etienne Javouhey; Pierre Cochat; Véronique Frémaux-Bacchi; Anne-Laure Sellier-Leclerc
Journal:  Pediatr Nephrol       Date:  2014-08-23       Impact factor: 3.714

Review 8.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

9.  Successful (?) therapy of hemolytic-uremic syndrome with factor H abnormality.

Authors:  Angela Gerber; Antje H Kirchhoff-Moradpour; Silke Obieglo; Matthias Brandis; Michael Kirschfink; Peter F Zipfel; Judith A Goodship; Lothar B Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2003-06-26       Impact factor: 3.714

Review 10.  aHUS caused by complement dysregulation: new therapies on the horizon.

Authors:  Aoife M Waters; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2010-06-18       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.